These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1076 related articles for article (PubMed ID: 32005219)

  • 1. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
    Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
    BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study.
    Huang TH; Kuo CW; Chen CW; Tseng YL; Wu CL; Lin SH
    BMC Pulm Med; 2021 May; 21(1):165. PubMed ID: 33992083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
    Ikeda K; Chiba H; Nishikiori H; Azuma A; Kondoh Y; Ogura T; Taguchi Y; Ebina M; Sakaguchi H; Miyazawa S; Suga M; Sugiyama Y; Nukiwa T; Kudoh S; Takahashi H;
    Respir Res; 2020 Nov; 21(1):316. PubMed ID: 33256760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
    Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
    Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
    Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
    Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
    Xue M; Guo Z; Cai C; Sun B; Wang H
    Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic performance of Krebs von den Lungen-6, surfactant protein A, surfactant protein D levels in the serum and bronchoalveolar lavage fluid in chronic fibrosing interstitial pneumonia: a retrospective study.
    Wakamatsu K; Nagata N; Kumazoe H; Hara M; Asai S; Noda N; Kiyotani R; Fukui I; Tatsuta M; Katahira K; Akasaki T; Maki S; Miyamoto K; Otsuka J; Izumi M; Kawasaki M; Yamada H
    BMC Pulm Med; 2024 Aug; 24(1):404. PubMed ID: 39174992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis.
    Hamai K; Iwamoto H; Ishikawa N; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Hattori N; Kohno N
    Dis Markers; 2016; 2016():4759040. PubMed ID: 27293304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D.
    Samukawa T; Hamada T; Uto H; Yanagi M; Tsukuya G; Nosaki T; Maeda M; Hirano T; Tsubouchi H; Inoue H
    BMC Pulm Med; 2012 Sep; 12():55. PubMed ID: 22963039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels.
    Koga Y; Hachisu Y; Tsurumaki H; Yatomi M; Kaira K; Ohta S; Ono J; Izuhara K; Dobashi K; Hisada T
    Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31108995
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation and management of Idiopathic Pulmonary Fibrosis.
    Kishaba T
    Respir Investig; 2019 Jul; 57(4):300-311. PubMed ID: 30853366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
    Xue C; Wu N; Li X; Qiu M; Du X; Ye Q
    BMC Pulm Med; 2017 Nov; 17(1):144. PubMed ID: 29149883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
    Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
    BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
    Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
    Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.
    Wang J; Zheng P; Huang Z; Huang H; Xue M; Liao C; Sun B; Zhong N
    BMC Pulm Med; 2020 Dec; 20(1):315. PubMed ID: 33267857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study.
    Lee HY; Jung SY; Jang JH; Ko J; Kim DW; Her M; Lee JH
    Life (Basel); 2023 Oct; 13(11):. PubMed ID: 38004258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis.
    Song JW; Do KH; Jang SJ; Colby TV; Han S; Kim DS
    Chest; 2013 May; 143(5):1422-1429. PubMed ID: 23715088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
    Cerri S; Monari M; Guerrieri A; Donatelli P; Bassi I; Garuti M; Luppi F; Betti S; Bandelli G; Carpano M; Bacchi Reggiani ML; Tonelli R; Clini E; Nava S
    Respir Med; 2019 Nov; 159():105803. PubMed ID: 31670147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.